minocycline and Syphilis

minocycline has been researched along with Syphilis* in 6 studies

Reviews

1 review(s) available for minocycline and Syphilis

ArticleYear
Efficacy and Safety of Treatments for Different Stages of Syphilis: a Systematic Review and Network Meta-Analysis of Randomized Controlled Trials and Observational Studies.
    Microbiology spectrum, 2022, 12-21, Volume: 10, Issue:6

    Parenteral penicillin is the first-line regimen for treating syphilis. However, allergic reactions and poor drug tolerance still present challenging problems with respect to use of this antibiotic. This study aimed to evaluate the efficacy and safety of ceftriaxone, erythromycin, minocycline, tetracycline, and doxycycline for syphilis treatment, compared with penicillin, to determine which antibiotic could be a better substitute for penicillin. This study included 17 articles, comprising 3 randomized controlled trials (RCTs) and 14 observational studies and involving 4,485 syphilis patients. Estimated risk ratios (RRs) and 95% confidence interval (CIs) were used to compare the serological response rates. At the 6- and 12-month follow-ups, the serological response rates were compared by direct meta-analysis and network meta-analysis (NMA). Based on direct meta-analysis, the serological response rates at the 3- and 24-month follow-ups were compared. Our NMA showed a higher serological response rate for ceftriaxone than for penicillin at the 6-month follow-up (RR of 1.12, 95% CI of 1.02 to 1.23). Ceftriaxone was equally effective as penicillin for syphilis in terms of serological response rates, and it was a better substitute for penicillin than ceftriaxone, erythromycin, minocycline, tetracycline, or doxycycline. However, more large-scale, high-quality, double-blind trials are still needed to determine whether ceftriaxone can safely replace penicillin for the treatment of syphilis when necessary.

    Topics: Anti-Bacterial Agents; Ceftriaxone; Doxycycline; Erythromycin; Humans; Hypersensitivity; Minocycline; Network Meta-Analysis; Observational Studies as Topic; Penicillins; Randomized Controlled Trials as Topic; Syphilis; Tetracycline

2022

Other Studies

5 other study(ies) available for minocycline and Syphilis

ArticleYear
Efficacy of minocycline in the treatment of early syphilis.
    International journal of STD & AIDS, 2021, Volume: 32, Issue:7

    Syphilis is the third prevalent infectious disease in China, caused by the spirochete bacterium

    Topics: Anti-Bacterial Agents; Humans; Minocycline; Penicillin G Benzathine; Retrospective Studies; Syphilis; Syphilis Serodiagnosis; Treponema pallidum

2021
Secondary Syphilis with Pulmonary Involvement.
    Internal medicine (Tokyo, Japan), 2018, Jan-01, Volume: 57, Issue:1

    A 39-year-old Japanese man presented to our hospital complaining of left chest pain and rash on the hands and feet. Plain thoracic computed tomography (CT) revealed multiple nodular shadows in the left lower lobe of the lung. A diagnosis of secondary syphilis was made based on the appearance of the rash and positive serologic tests for syphilis. The patient was started on amoxicillin but was switched to minocycline due to amoxicillin-induced rash on both forearms. Thoracic CT after five months of treatment revealed that the multiple lung nodular shadows had contracted, and secondary syphilis with pulmonary involvement was diagnosed.

    Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Asian People; Humans; Lung; Male; Minocycline; Serologic Tests; Syphilis; Tomography, X-Ray Computed; Treatment Outcome; Treponema pallidum

2018
Could lengthening minocycline therapy better treat early syphilis?
    Medicine, 2016, Volume: 95, Issue:52

    Syphilis is a sexually transmitted disease caused by Treponema pallidum. Minocycline, a representative tetracycline derivative, has the greatest antimicrobial activity among all tetracyclines. There are few reports about treating syphilis with minocycline because there is a lack of efficacy data from controlled trials. We compared the rates of serological cure in patients with early syphilis who were treated with minocycline or benzathine penicillin G (BPG).During the study period, a total of 40 syphilis patients received the BPG treatment, which was a single intramuscular dose of 2.4 million units of BPG, and 156 patients were treated with minocycline; 77 patients were placed in the 2-week, standard minocycline therapy group and received 100 mg of minocycline orally, twice daily for 14 days, and 79 patients were placed in the 4-week, lengthened minocycline therapy group and received 100 mg of minocycline orally, twice daily for 28 days. The outcome of interest was the rate of serological cure in these patients.At the end of the 2-year follow-up, the serological cure rate of the 4-week, lengthened minocycline therapy group (87.34%) was higher than that of both the 2-week, standard minocycline therapy group (72.73%) and the BPG treatment group (77.50%). In addition, the curative effect of the 4-week, lengthened minocycline therapy was significantly greater than that of the 2-week, standard minocycline therapy in patients who were aged >40 years; exhibited an initial rapid plasma reagin titer ≥1: 32; or exhibited secondary syphilis (P = 0.000, 0.008, 0.000; <0.05).Minocycline appears to be an effective agent for treating early syphilis, especially when applied as a 4-week, lengthened therapy.

    Topics: Adult; Age Factors; Anti-Bacterial Agents; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Minocycline; Penicillin G Benzathine; Reagins; Retrospective Studies; Syphilis; Young Adult

2016
Malignant syphilis with ocular involvement in an HIV-infected patient.
    International journal of STD & AIDS, 2011, Volume: 22, Issue:5

    Malignant syphilis is now considered a rare disease, more commonly affecting individuals with poor health, malnutrition or HIV infection. We present a 34-year-old man with HIV infection who developed multiple atypical cutaneous ulcerations, leonine facies, a scleral nodule and keratitis with visual loss. The diagnosis of malignant syphilis was delayed due to the insidious presentation, but was confirmed via immunohistochemical (IHC) staining with anti-Treponema antibodies of a skin biopsy. Significant clinical improvement was observed following a 15-day course of penicillin and tigecycline therapy. In advanced HIV disease, cutaneous manifestations are often difficult to identify and present a challenge for the clinician. Clinical manifestations of secondary syphilis vary greatly, earning the epigram of 'the great imitator'. It is important to recognize atypical presentations of syphilis, especially among HIV-infected individuals. Unlike historical cases of malignant syphilis, Treponema pallidum was found in the tissue section using IHC staining methods. We emphasize the importance of lues maligna in the differential diagnosis of HIV-infected patients with diffuse ulceronodular lesions as well as the usefulness of histological investigations and IHC studies.

    Topics: Adult; Anti-Bacterial Agents; Biopsy; Eye Diseases; HIV Infections; Humans; Immunohistochemistry; Male; Minocycline; Penicillins; Syphilis; Tigecycline; Treatment Outcome; Treponema pallidum

2011
Minocycline in the treatment of lymphogranuloma venereum.
    Journal of the American Venereal Disease Association, 1976, Volume: 2, Issue:4

    In a study of 80 cases of lymphogranuloma venereum (LGV), minocycline hydrochloride (Minocin) was found to be an effective drug in the treatment of all stages of LGV, including complicated ones. In late cases adjuvant treatment was used in addition to the antibiotic. Healing time in uncomplicated cases was less than 10 days. In complicated cases, both early and late, healing took about 2 to 3 weeks. Reactions to the drug were not significant.

    Topics: Adolescent; Adult; Chlamydia; Female; Humans; Lymph Nodes; Lymphogranuloma Venereum; Male; Minocycline; Prednisolone; Rectal Diseases; Syphilis; Tetracyclines

1976